Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the Eu...
Aileron Therapeutics, Inc. (ALRN)
Last aileron therapeutics, inc. earnings: 11/7 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aileronrx.com
Company Research
Source: GlobeNewswire
New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cellsEncore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles and their stem cellsEx vivo data demonstrated protection against taxane-induced damage to hair follicles and their stem cells Nearly all breast cancer patients receiving neoadjuvant or adjuvant chemotherapy, including cyclophosphamide and taxanes, such as docetaxel, experience alopecia (hair loss)Aileron is evaluating ALRN-6924 as a novel chemoprotective agent to prevent chemotherapy-induced bone marrow toxicities and alopecia in its ongoing Phase 1b breast cancer trial BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced
Show less
Read more
Impact Snapshot
Event Time:
ALRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALRN alerts
High impacting Aileron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALRN
News
- Aileron Therapeutics, Inc. (NASDAQ: ALRN) had its price target raised by analysts at LADENBURG THALM/SH SH from $9.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Aileron Therapeutics Announces CEO Transition [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Announces CEO TransitionGlobeNewswire
ALRN
Analyst Actions
- 4/18/24 - Ladenburg Thalmann
ALRN
Sec Filings
- 4/16/24 - Form SC
- 4/15/24 - Form 10-K
- 4/15/24 - Form 8-K
- ALRN's page on the SEC website